Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Fresenius Obtains Reimbursement Approval for Removab in Belgium

Don't Miss Out —
Follow us on:

Oct. 4 (Bloomberg) -- Fresenius Biotech said the Belgian Health Ministry added its trifunctional antibody Removab to the list of reimbursable medications as of Oct. 1. The use of Removab will be reimbursed if the eligible patients also fulfill defined additional clinical inclusion criteria, the company said in an e-mailed statement today.

Link to Company News:{FME GR <Equity> CN <GO>} Link to Company News:{FRE GR <Equity> CN <GO>}

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.